The effectiveness and safety of DUPIXENT has been studied in the largest clinical trials to date for CRSwNP with 724 adults with uncontrolled chronic rhinosinusitis with nasal polyposis (CRSwNP).

• In both studies, DUPIXENT was proven to help patients breathe better by relieving nasal congestion and reducing the size of nasal polyps compared to placebo group.

Patients enrolled in these studies included subjects with CRSwNP regardless of whether they had prior sino-nasal surgery or treatment with, or who were ineligible to receive or were intolerant to, systemic corticosteroids in the past 2 years. Patients with chronic rhinosinusitis without nasal polyposis were not included in these trials.